Role of pharmacists in optimizing the use of anticancer drugs in the clinical setting

References

• Morris CR, Hickman MJ. Medical oncology pharmacy: a new role for the clinical pharmacist. Am J Pharm Educ. 1977;41:278–280.
   Web of Science ®Google Scholar
• [No authors listed]. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990;47:1033–1049.
   Google Scholar
• American Society of Hospital Pharmacists. ASHP statement on pharmaceutical care. Am J Hosp Pharm. 1993;50:1720–1723.
   Google Scholar
• [No authors listed]. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993;50:305–314.
   Google Scholar
• ASHP Council on Professional Affairs. ASHP guidelines on preventing medication errors with antineoplastic agents. Am J Health-Syst Pharm. 2002;59:1648–1668.
   Web of Science ®Google Scholar
• Board of Pharmacy Specialies. [webpage on the Internet] http://www.bpsweb.org/about/history.cfm. Accessed January 25, 2014.
   Google Scholar
• American College of Clinical Pharmacy. Frequently asked questions about board certification. Available from: https://www.accp.com/careers/boardfaq.aspx. Accessed September 1, 2013.
   Google Scholar
• Cancer.Net. ASCO expert corner: the role of the oncology pharmacist. Available from: http://www.cancer.net/all-about-cancer/cancernet-feature-articles/expert-information-asco/asco-expert-corner-role-oncology-pharmacist. Accessed November 1, 2013.
   Google Scholar
• Joint Commission. About our standards. Available from: http://www.jointcommission.org/standards_information/standards.aspx. Accessed October 22, 2013.
   Google Scholar
• Council on Credentialing in Pharmacy, Albanese NP, Rouse MJ. Scope of contemporary pharmacy practice: roles, responsibilities, and functions of pharmacists and pharmacy technicians. J Am Pharm Assoc (2003). 2010;50:e35–e69.
   Web of Science ®Google Scholar
• Wong WM, Ignoffo RF. If there are expert systems and dose checks, why do we still need the clinical pharmacist? Pharm Pract Manage Q. 1996;16:50–58.
   PubMedGoogle Scholar
• O’Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol. 2012;6:251–259.
   PubMed Web of Science ®Google Scholar
• Moen El, Godley LA, Zhang W. Dolan ME. Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med. 2012;4:90.
   Web of Science ®Google Scholar
• Taylor JA, Winter L, Geyer LJ, Hawkins DS. Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia. Cancer. 2006;107;1400–1406.
   Web of Science ®Google Scholar
• Beyzarov E. High rate of drug errors seen in pediatric oncology. Pharm Pract News. 2006;33:10.
   Google Scholar
• Bates DW, Boyle DL, Vander Vliet MB, Schneider J, Leape L. Relationship between medication errors and adverse drug events. J Gen Intern Med. 1995:10:199–205
   Web of Science ®Google Scholar
• Gandhi TK, Weingart SN, Seger AC, et al. Outpatient prescribing errors and the impact of computerized prescribing. J Gen Intern Med. 2005;20:837–841.
   Web of Science ®Google Scholar
• Goldspiel BR, DeChristoforo R, Daniels CE. A continuous-improvement approach for reducing the number of chemotherapy-related medication errors. J Health Syst Pharm. 2000;57 Suppl 4: S4–S9.
   Google Scholar
• Cohen MR, Anderson RW, Attilio RM, Green L, Muller RJ, Pruemer JM. Preventing medication errors in cancer chemotherapy. Am J Health Syst Pharm. 1996;53:737–746.
   Web of Science ®Google Scholar
• Brink S. Tragedy at Dana-Farber: Betsy Lehman’s shocking death is still roiling the medical community. 1995. Available from: http://health.usnews.com/usnews/health/articles/950724/archive_032493.htm. Accessed December 28, 2013.
   Google Scholar
• Pastel DA, Fay P, Lee D. Effect of implementing a cancer chemotherapy order form on prescribing habits for parenteral antineoplastics. Hosp Pharm. 1993;28:1192–1195.
   Google Scholar
• Serrano-Fabiá A, Albert-Marí A, Almenar-Cubells D, Jiménez- Torres NV, Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy. J Oncol Pharm Pract. 2010;16: 105–112.
   Google Scholar
• Kim GR, Chen AR, Arceci RJ, et al. Error reduction in pediatric chemotherapy: computerized order entry and failure modes and effects analysis. Arch Pediatr Adolesc Med. 2006;160:495–498.
   Google Scholar
• Surveillance, Epidemiology, and End Results Program. SEER cancer statistics review (CSR) 1975–2010. 2013. Available from: http://seer.cancer.gov/csr/1975_2010. Accessed November 1, 2013.
   Google Scholar
• Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32:169–175.
   PubMed Web of Science ®Google Scholar
• Safran D, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood). 2005;Suppl Web Exclusives: W5-152–W5-166.
   Web of Science ®Google Scholar
• Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107–1116.
   PubMed Web of Science ®Google Scholar
• Ladas EJ, Sacks N, Meacham L, et al. A multidisciplinary review of nutrition considerations in the pediatric oncology population: a perspective from children’s oncology group. Nutr Clin Pract. 2005;20:377–393.
   PubMedGoogle Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology – drug disposition, action and therapy in infants and children. N Engl J Med. 2003;349: 1157–1167.
   PubMed Web of Science ®Google Scholar
• Carr R, Ensom M. Drug disposition and therapy in adolescence: the effects of puberty. J Pediatr Pharmacol Ther. 2003;8:86–96.
   Google Scholar
• Krishnaswamy K. Drug metabolism and pharmacokinetics in malnourished children. Clin Pharmacokinet. 1989;17 Suppl 1:68–88.
   Google Scholar
• Murray DJ, Riva L, Poplack DG. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl. 1998;11:48–51.
   Google Scholar
• Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999;88:1–7.
   PubMed Web of Science ®Google Scholar
• Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39:215–231.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol. 1998;6:1321–1327.
   Google Scholar
• Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther. 1991;49:536–549.
   Web of Science ®Google Scholar
• Relling MV. Pharmacogenomics of adverse effects of anti-leukemic agents in children. J Pediatr Pharmacol Ther. 2012;17(1):7–11.
   Google Scholar
• Crews KR, Cross SJ, McCormick JN, Baker DK, et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm. 2011;68:143–150.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. A review of FDA’s approach to medical product shortages. 2011. Available from: http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm275051.htm. Accessed October 22, 2013.
   Google Scholar
• McBride A, Holle LM, Westerndorf C, et al. National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm. 2013;70:609–617.
   Web of Science ®Google Scholar
• Metzger ML, Billett A, Link M. Impact of drug shortages on children with cancer – the example of mechlorethamine. New Engl J Med. 2012;367:2461–2463.
   PubMed Web of Science ®Google Scholar
• American Society of Health-System Pharmacists. Dacarbazine injection. 2013. http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=949. Accessed October 19, 2013.
   Google Scholar
• Plevin DM, Ward HM, Ward MB, Sorich MJ, McKinnon RA. Pharmacist’s role in targeted cancer therapy in Australia and implications for pharmacy education. Am J Pharm Educ. 2010;74:168.
   Web of Science ®Google Scholar
• Jones S. Pharmacy practice issues with targeted therapy for lung cancer. Am J Health-Syst Pharm. 2003;60:11–15.
   Web of Science ®Google Scholar
• Joint Commission. Look-alike/sound-alike drug list. 2011. Available from: http://www.jointcommission.org/LASA. Accessed October 22, 2013.
   Google Scholar
• Institute for Safe Medication Practices. ISMP’s list of confused drug names. 2011. Available from: http://www.ismp.org/Tools/confuseddrugnames.pdf. Accessed October 22, 2013.
   Google Scholar
• Becton Dickinson. BD PhaSeal closed system transfer device. 2013. Available from: http://www.BD.com/pharmacy/phaseal. Accessed November 2, 2013.
   Google Scholar
• ICU Medical [website on the Internet]. Available from: http://www.icumedical.com. Accessed November 2, 2013.
   Google Scholar
• Tanaka GJ, Fujiwara J, Kramer H, Bredt AB, Wortmann M. Justification and implementation of an oncology pharmacist practitioner in an HMO setting. Hosp Pharm. 1985;20:568–574.
   Google Scholar
• Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–543.
   PubMedGoogle Scholar
• Schochet SS Jr, Lampert PW, Earle KM. Neuronal changes induced by intrathecal vincristine sulfate. Neuropathol Exp Neurol. 1968;27:645–658.
   PubMed Web of Science ®Google Scholar
• Bain PG, Lantos PL, Djurovic V, West I. Intrathecal vincristine: a fatal chemotherapeutic error with devastating central nervous system effects. J Neurol. 1991;238:230–234.
   PubMed Web of Science ®Google Scholar
• Lagman JL, Tigue CC, Trifilio SM, et al. Inadvertent intrathecal administration of vincristine. Community Oncol. 2007;4:45–46.
   Google Scholar
• Joint Commission [website on the Internet]. Available from: http://www.jointcommission.org. Accessed November 2, 2013.
   Google Scholar
• Lexicomp [website on the Internet]. Available from: http://www.lexicomp.com. Accessed December 27, 2013.
   Google Scholar
• Berard CM, Mahoney CD. Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting. Am J Health Syst Pharm. 1995;52:1879–1885.
   Web of Science ®Google Scholar
• Iihara, H, Ishihara M, Matsuura K, et al. Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J Eval Clin Prac. 2010;18:753–760.
   Web of Science ®Google Scholar
• Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–4198.
   PubMed Web of Science ®Google Scholar
• DeWit R, Herstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin based chemotherapy. J Clin Oncol. 2003;21:4105–4111.
   Web of Science ®Google Scholar
• Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–2830.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–4119.
   PubMed Web of Science ®Google Scholar
• Bubalo JS, Cherala G, McCune JS, Munar MY, Tse S, Maziarz R. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol. 2012;52:586–594.
   PubMed Web of Science ®Google Scholar
• Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract. 2010;16: 45–51.
   PubMedGoogle Scholar
• Uchida M, Ikesue H, Kato K, et al. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. Am J Health Syst Pharm. 2013;70:343–349.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical practice guideline in oncology – antiemesis v1.2012. Available from: www.NCCN.org/professionals/physician-gls/f_guidelines.asp#antiemesis-NCCNclinicalpracticeguidelinesinoncology. Accessed November 5, 2013.
   Google Scholar
• Hesketh PJ, Warr DG, Street JC, Carides AD. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). Support Care Cancer. 2011;19:1297–1302.
   PubMed Web of Science ®Google Scholar
• Chan AC, Shih V, Chew L. Evolving roles of oncology pharmacists in Singapore: a survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre. J Oncol Pharm Pract. 2008;14:23–29.
   Google Scholar
• US Food and Drug Administration. Drugs: hematology/oncology (cancer) approvals and safety notifications. Available from: http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm#updates. Accessed October 30, 2013.
   Google Scholar
• Weingart SN, Spencer J, Buia S, et al. Medication safety of five oral chemotherapies: a proactive risk assessment. J Oncol Pract. 2011;7:2–6.
   PubMedGoogle Scholar
• Backes K, Griesbach S, Wilhelm S, Plank G. Identification of drug therapy opportunities with oral chemotherapy. 2013. Available from: http://www.specialtypharmacytimes.com/publications/specialty-pharmacy-times/2013/May_June-2013/Identification-of-Drug-Therapy-Opportunities-with-Oral-Chemotherapy. Accessed December 27, 2013.
   Google Scholar
• Weingart SN, Flug J, Brouillard D, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ. 2007;334:407.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652–662.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P. Dose response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304:10–15.
   PubMed Web of Science ®Google Scholar
• Porzsolt F, Meuret G, Kreuser ED, et al. Compliance of physicians and patients with a consensus protocol for treatment of advanced breast cancer. J Cancer Res Clin Oncol. 1994;115:564–570.
   Google Scholar
• Spiegel D. Psychosocial aspects of breast cancer treatment. Semin Oncol. 1997;24:S136–S147.
   Web of Science ®Google Scholar
• Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR. Patient noncompliance with self-administered chemotherapy. Cancer. 1990;65:17–22.
   PubMed Web of Science ®Google Scholar
• Levine AM, Richardson JL, Marks G, et al. Compliance with oral drug therapy in patients with hematological malignancy. J Clin Oncol. 1987;5:1469–1476.
   PubMed Web of Science ®Google Scholar
• Viele CS. Managing oral chemotherapy: the healthcare practitioner’s role. Am J Health Syst Pharm. 2007;64:S25–S32.
   PubMed Web of Science ®Google Scholar
• Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151:1842–1847.
   PubMed Web of Science ®Google Scholar
• Gandhi TK, Bartel SV, Shulman LN, et al. Medication safety in the ambulatory chemotherapy setting. Cancer. 2005;104:2477–2483.
   PubMed Web of Science ®Google Scholar
• Cherny NI. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage. 2008;36:413–423.
   PubMed Web of Science ®Google Scholar
• Maroun JA, Anthony LB, Blais N. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol. 2007;14: 13–20.
   PubMedGoogle Scholar
• ASPEN Board of Directors and the Clinical Guidelines Task Forces. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr. 2002;26:1SA–1388SA.
   Google Scholar
• American Society for Parenteral and Enteral Nutrition. Clinical nutrition critical care guidelines released [press release]. Silver Spring (MD): ASPEN; April 27, 2009. Available from: http://www.nutritioncare.org/News/Clinical_Nutrition_Critical_Care_Guidelines_Released. Accessed November 3, 2013.
   Google Scholar
• Mauer AM, Burgess JB, Donaldson SS, et al. Special nutritional needs of children with malignancies: a review. J PEN J Parenter Enteral Nutr. 1990;14:315–324.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Hoffman JP, Ottery FD. Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition. 2001;17:S1–S20.
   PubMed Web of Science ®Google Scholar
• Dunn R, Stettler N, Mascarenhas M. Refeeding syndrome in hospitalized pediatric patients. Nutr Clin Pract. 2003;18: 327–332.
   Google Scholar
• Briceland LL, Lomaestro BM, Griswold MW, Lesar TS. Interventions in antimicrobial therapy made by infectious diseases clinical pharmacy specialists. J Infect Dis Pharmacother. 1999;(4):319–331.
   Google Scholar
• Masiá M, Matoses C, Padilla S, et al. Limited efficacy of a nonrestricted intervention on antimicrobial prescription of commonly used antibiotics in the hospital setting: results of a randomized controlled trial. Eur J Clin Microbiol Infect Dis. 2008;27:597–605.
   Web of Science ®Google Scholar
• Cappelletty D, Jacobs D. Evaluating the impact of a pharmacist’s absence from an antimicrobial stewardship team. Am J Health Syst Pharm. 2013;70:1065–1069.
   Web of Science ®Google Scholar
• Dunn K, O’Reilly A, Silke B, Rogers T, Bergin C. Implementing a pharmacist-led sequential antimicrobial therapy strategy: a controlled before-and-after study. Int J Clin Pharm. 2011;33:208–214.
   PubMed Web of Science ®Google Scholar
• Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicenter, randomized trial. BMJ. 2006;333:1193–1198.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention strategies for seasonal influenza in healthcare settings. 2013. Available from: http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm. Accessed October 28, 2013.
   Google Scholar
• Dellit TH, Owens Rc, McGowan JEJr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–177.
   PubMed Web of Science ®Google Scholar
• Drew RH, White RW, MacDougall C, Hermsen ED, Owens RC. Insights from the Society of Infectious Diseases pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Pharmacotherapy. 2009;29:593–607.
   PubMed Web of Science ®Google Scholar
• MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev. 2005;18:638–656.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. ASHP statement on the pharmacist’s role in antimicrobial stewardship and infection prevention and control. Am J Health Syst Pharm. 2010;67:575–577.
   Google Scholar
• Chew L, Chuen VS. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract. 2009;15:29–34.
   Google Scholar
• Valgus JM, Faso A, Gregory KM, et al. Integration of a clinical pharmacist into the hematology-oncology clinics at an academic medical center. Am J Health Syst Pharm. 2011;68:613–619.
   PubMed Web of Science ®Google Scholar
• Broadfield L. Pharmaceutical care in oncology pharmacy practice: a method for using outcome indicators. J Oncol Pharm Pract. 1995;1:9–14.
   Google Scholar
• Schwappach DL, Wernli M. Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature. Eur J Cancer Care (Engl). 2010;19:285–292.
   PubMed Web of Science ®Google Scholar
• Shah S, Dowell J, Greene S. Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Ann Pharmacother. 2006;40:1527–1533.
   Web of Science ®Google Scholar
• McKee M, Frei BL, Garcia A, Fike D, Soefje SA. Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic. J Oncol Pharm Pract. 2010;17:387–394.
   Google Scholar
• Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm. 2007;64:S4–S7.
   PubMed Web of Science ®Google Scholar
• Hartigan K. Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs. 2003;7:21–24.
   Google Scholar
• Pituskin E, Fairchild A, Dutka J, et al. Multidisciplinary team contributions within a dedicated outpatient palliative radiotherapy clinic: a prospective descriptive study. Int J Radiat Oncol Biol Phys. 2010;78: 527–532.
   PubMed Web of Science ®Google Scholar
• Steiber D. Oncology? The brass ring? 2013. Available from: http://www.specialtypharmacytimes.com/publications/specialty-pharmacy-times/2013/May_June-2013/Oncology-The-Brass-Ring. Accessed December 27, 2013.
   Google Scholar
• Jones KL, Garnett C, Gauthier M, Boster B, Espirito JL, Michaud LB. Clinical outcomes of a pharmacist-managed anticoagulation service for breast cancer patients. J Oncol Pharm Pract. 2011;18: 122–127.
   Google Scholar
• Bartel SB. Safe practices and financial considerations in using oral chemotherapeutic agents. Am J Health Syst Pharm. 2007;64:S8–S14.
   Web of Science ®Google Scholar
• Lacouture ME, Anaadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079–1095.
   PubMed Web of Science ®Google Scholar
• Wood LS, Lemont H, Jatoi A, et al. Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Community Oncol. 2010;7:23–29.
   Google Scholar
• Panglilinan JA. Venous thromboembolism in patients with cancer: an overview for pharmacists using a case-based approach. J Pharm Pract. 2010;23:294–302.
   Google Scholar
• Read H, Ladds S, Rhodes B, Brown D, Portlock J. The impact of supplementary medication review and counseling service within the oncology outpatient setting. Br J Cancer. 2007;96:744–751.
   Web of Science ®Google Scholar
• Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–1850.
   PubMed Web of Science ®Google Scholar
• Rose AJ, Sharmann JP, Ozonoff A, Henault LE, Hylek EM. Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007;22:997–1002.
   Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohn DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population based case-control study. Arch Intern Med. 2000;160:809–815.
   PubMed Web of Science ®Google Scholar
• Saif MW. An adverse reaction between warfarin and fluoropyrimidines revisited. Clin Colorectal Cancer. 2005;5:175–180.
   PubMedGoogle Scholar
• Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004;101:439–449.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100: 3484–3488.
   PubMed Web of Science ®Google Scholar
• Hutten BA, Prins MH, Gent M, Ginsberg J. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078–3083.
   PubMed Web of Science ®Google Scholar
• Hutchison LC, Castleberry A. The pharmacist’s new role as part of an interdisciplinary care team. J Am Soc Aging. 2012;35:62–68.
   Google Scholar
• Liekweg A, Westfeld M, Jaehde U. From oncology pharmacy to pharmaceutical care: new contributions to multidisciplinary cancer care. Support Care Cancer. 2004;12:73–79.
   PubMed Web of Science ®Google Scholar